The study of platelet microparticles and P-selectin expression in patients with the peripheral arterial diseases
- Authors: Ermakov A.I.1, Gaikovaya L.B.2, Sirotkina O.V.3,4, Vavilova T.V.3
-
Affiliations:
- St. Petersburg City AIDS Center
- North-Western State Medical University named after I.I. Mechnikov
- Almazov National Medical Research Centre
- Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre “Kurchatov Institute”
- Issue: Vol 23, No 1 (2023)
- Pages: 107-114
- Section: Clinical research
- Published: 22.05.2023
- URL: https://journals.eco-vector.com/MAJ/article/view/296568
- DOI: https://doi.org/10.17816/MAJ296568
- ID: 296568
Cite item
Abstract
BACKGROUND: High platelet reactivity leads to the progression of atherosclerosis and its complications. Activated platelets adhere to the site of endothelium damage on the vessel wall and initiate the formation of an arterial thrombus, followed by acute ischemia of the organ. Biochemical and cellular marker such as platelet microvesicles and P-selectin can be analyzed using flow cytometry, which is based on a specific antigen-antibody interaction. Patients with peripheral arterial disease are at significantly greater risk of cardiovascular and cerebrovascular complications than individuals of the same age and sex. The use of antiplatelet agents is an important part of pathogenetic therapy and prevention of cardiovascular diseases and their complications.
AIM: This study was to evaluate the level of platelet microparticles and P-selectin expression in patients with peripheral arterial disease receiving antiplatelet therapy.
MATERIALS AND METHODS: The study included 49 people, which included three study groups: patients with obliterating disease of the arteries of the lower extremities (n = 14) on the background of long-term use (more than 14 days) of double (75 mg clopidogrel and 100 mg Acetylsalicylic acid) antiplatelet therapy, patients with COVID-19 (n = 15), who made up the positive control group in the determination of microparticles of platelet origin, and healthy volunteers (n = 20) without signs of acute respiratory disease, without a history of cardiovascular and thromboembolic episodes, not taking antiplatelet drugs. The functional activity of platelets was assessed by two methods: using light aggregometry and analysis of P-selectin expression on platelet surface by flow cytometry. The number of platelet’s microparticles in blood plasma was also determined using flow cytometry.
RESULTS: A significant decrease in platelet aggregation was found in patients with peripheral arterial disease taking antiplatelet agents, compared with controls by used light aggregometry. Similar changes were obtained when analyzing the expression of P-selectin on platelets. A higher percentage of platelet’s microparticles with the CD9+CD41+ phenotype was found in patients with severe inflammation compared with peripheral arterial disease patients treated with antiplatelet agents and compared with the healthy controls.
CONCLUSIONS: Thus, our study reflects the consistency of the results of three different laboratory tests in assessing the platelets reactivity in patients with the peripheral arterial diseases taking antiplatelet drugs.
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
About the authors
Aleksei I. Ermakov
St. Petersburg City AIDS Center
Author for correspondence.
Email: Ermakovspb@mail.ru
ORCID iD: 0000-0003-3435-5881
SPIN-code: 8921-7251
Head of Clinical Laboratory Department
Russian Federation, Санкт-ПетербургLarisa B. Gaikovaya
North-Western State Medical University named after I.I. Mechnikov
Email: Larisa.Gaikovaya@szgmu.ru
ORCID iD: 0000-0003-1000-1114
SPIN-code: 9424-1076
MD, Dr. Sсi. (Med.), Professor, Head of Sokolovsky Department of Biological and General Chemistry
Russian Federation, Saint PetersburgOlga V. Sirotkina
Almazov National Medical Research Centre; Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre “Kurchatov Institute”
Email: Olga_sirotkina@mail.ru
ORCID iD: 0000-0003-3594-1647
SPIN-code: 1780-5490
Dr. Sci. (Biol.), Professor of Department of Laboratory Medicine and Genetics; Senior Research Associate of Laboratory of Human Molecular Genetics
Russian Federation, Saint Petersburg; GatchinaTatiana V. Vavilova
Almazov National Medical Research Centre
Email: Vtv.lab.spb@gmail.com
ORCID iD: 0000-0001-8537-3639
SPIN-code: 9003-6455
Scopus Author ID: 7004477312
MD, Dr. Sci. (Med.), Professor, Head of Department of Laboratory Medicine and Genetics
Russian Federation, Saint PetersburgReferences
- Еnjeti AK, Lincz LF, Seldon M. Detection and measurement of microparticles: an evolving research tool for vascular biology. Semin Thromb Hemost. 2007;33(8):771–779. doi: 10.1055/s-2007-1000369
- Storey R, Judge H, Wilcox RG, Heptinstall S. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thromb Haemost. 2002;88(3):488–494.
- Borissoff JI, Spronk HM, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med. 2011;364(18):1746–1760. doi: 10.1056/NEJMra1011670
- Polyakov PI, Gorelik SG, Zheleznova EA. Obliterating atherosclerosis of lower extremities in the eldery patients. Journal of New Medical Technologies. 2013;20(1):98–101. (In Russ.)
- Dormandy J, Mahir H, Ascady G, et al. Fate of the patient with chronic leg ischemia. A review article. J Cardiovasc Surg (Torino). 1989;30(1):50–57.
- van der Zee PM, Biro E, Ko Y, et al. P-selection and CD63-exposing platelet microparticles reflect platelet activation in peripheral arterial disease and myocardial infarct. Clin Chem. 2006;52(4):657–664. doi: 10.1373/clinchem.2005.057414
- McEver RP, Beckstead JH, Moore KL, et al. GMP-140, a platelet alpha-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel–Palade bodies. J Clin Invest.1989;84(1):92–99. doi: 10.1172/JCI114175
- Biasucci LM, Porto I, Di Vito L, et al. Differences in microparticle release in patients with acute coronary syndrome and stable angina. Circ J. 2012;76(9):2174–2182. doi: 10.1253/circj.cj-12-0068
- Nieuwland R, Berckmans RJ, Rotteveel-Eijkman RC, et al. Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation. 1997;96(10):3534–3541. doi: 10.1161/01.cir.96.10.3534
- Veira AJ, Mooberry M, Key NS. Microparticles in cardiovascular disease pathophysiology and outcomes. J Am Soc Hypertens. 2012;6(4):243–252. doi: 10.1016/j.jash.2012.06.003
- Dake MD, Ansel GM, Jaff MR, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoro-popliteal artery: 5-Year Results of the Zilver PTX Randomized Trial. Circulation. 2016;133(15):1472–1483. doi: 10.1161/CIRCULATIONAHA.115.016900
- Laird JR, Schneider PA, Tepe G, et al. Durability of treatment effect using a drug-coated balloon for femoro-popliteal lesions. J Am Coll Cardiol. 2015;66(21):2329–2338. doi: 10.1016/j.jacc.2015.09.063
- Franzone A, Piccolo R, Gargiulo G, et al. Prolonged vs short duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with or without peripheral arterial disease. JAMA Cardiol. 2016;1(7):795–803. doi: 10.1001/jamacardio.2016.2811
- Bonaca MP, Bhatt DL, Storey RF, et al. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J Am Coll Cardiol. 2016;6(23):2719–2728. doi: 10.1016/j.jacc.2016.03.524
- Ault KA. The clinical utility of flow cytometry in the study of platelets. Semin Hematol. 2001;38(2):160–168. doi: 10.1016/s0037-1963(01)90049-6
- Kailashiy J. Platelet-derived microparticles analysis: Techniques, challenges and recommendations. Anal Biochem. 2018;546:78–85. doi: 10.1016/j.ab.2018.01.030
- Sirotkina OV, Bogankova NA, Laskovec AB, et al. Immunological methods for assessing the functional activity of platelets in patients with cardiovascular diseases. Medical immunology. 2010;12(3):213–218. (In Russ.) doi: 10.15789/1563-0625-2010-3-213-218
- Sirotkina OV, Ermakov AI, Gaykovaya LB, et al. Microparticles of blood cells in patients with COVID-19 as a marker of hemostasis activation. Tromboz, Gemostaz i Reologiya. 2020;(4):35–40. (In Russ.) doi: 10.25555/THR.2020.4.0943
- Li X., Cong H. Platelet-derived microparticles and the potential of glycoprotein IIb/IIIa antagonists in treating acute coronary syndrome. Tex Heart Inst J. 2009;36(2):134–139.
- Vavilova TV, Sirotkina OV, Ermakov AI, et al. Molecular mechanisms of hemostasis activation in COVID-19 at the hospital stage. Laboratory Service. 2021;10(4):25–29. (In Russ.) doi: 10.17116/labs20211004125
- Sirotkina OV, Ermakov AI, Zhilenkova YuI, et al. Dynamics of microvesicle formation in blood in patients with COVID-19 at different stages of the disease. Preventive and clinical medicine. 2021;4(81):68–74. (In Russ.) doi: 10.47843/2074-9120_2021_4_68
Supplementary files
![](/img/style/loading.gif)